HDL Cholesterol Enhancer Drug Shows Early Promise

An experimental drug from Roche designed to raise “good” HDL cholesterol has produced promising results.

Now on its mid-stage clinical trial, the drug known as dalcetrapib will be released at a medical meeting in Paris next week its following data from the 130-patient imaging study showing it does not increase plaque-related inflammation on artery walls.

Furthermore, patients on the new drug had less build-up of potentially artery-clogging plaque in their blood vessel walls than those on placebo, and the medicine was well tolerated.

However, there’s no evidence yet, so far, that that raising HDL with drugs actually stops heart attacks and strokes.

View the original article here